

May 20th, 5:00 PM - 7:00 PM

## Validation of Acute Myocardial Infarction (AMI) in the FDA's Mini-Sentinel Distributed Database

Sarah L. Cutrona

*University of Massachusetts Medical School*

Darren Toh

*Harvard Pilgrim Health Care Institute, Boston*

Aarthi Iyer

*Harvard Pilgrim Health Care Institute, Boston*

*See next page for additional authors*

Follow this and additional works at: [http://escholarship.umassmed.edu/cts\\_retreat](http://escholarship.umassmed.edu/cts_retreat)



Part of the [Biostatistics Commons](#), and the [Systems Biology Commons](#)

---

Cutrona, Sarah L.; Toh, Darren; Iyer, Aarthi; Foy, Sarah; Cavagnaro, Elizabeth; Forrow, Susan; Goldberg, Robert J.; and Gurwitz, Jerry H., "Validation of Acute Myocardial Infarction (AMI) in the FDA's Mini-Sentinel Distributed Database" (2011). *UMass Center for Clinical and Translational Science Research Retreat*. 2.

[http://escholarship.umassmed.edu/cts\\_retreat/2011/posters/2](http://escholarship.umassmed.edu/cts_retreat/2011/posters/2)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

---

**Presenter Information**

Sarah L. Cutrona, Darren Toh, Aarthi Iyer, Sarah Foy, Elizabeth Cavagnaro, Susan Forrow, Robert J. Goldberg, and Jerry H. Gurwitz

**Creative Commons License**

This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/).

# Validation of Acute Myocardial Infarction (AMI) in the FDA's Mini-Sentinel Distributed Database

Sarah L. Cutrona, MD, MPH,<sup>1</sup> Darren Toh, ScD,<sup>2</sup> Aarthi Iyer, MPH,<sup>2</sup> Sarah Foy, BA,<sup>1</sup> Elizabeth Cavagnaro, BA,<sup>2</sup> Susan Forrow, BA,<sup>2</sup> Robert Goldberg, PhD,<sup>1</sup> Jerry H. Gurwitz, MD<sup>1</sup>

- 1) University of Massachusetts Medical School and the Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Clinic, and Fallon Community Health Plan, Worcester, MA  
2) Harvard Pilgrim Health Care Institute, Boston, MA

## Background

The Food and Drug Administration's (FDA) Mini-Sentinel is a pilot program that aims to conduct active surveillance to detect and refine safety signals that emerge for marketed medical products.

The purpose of this Mini-Sentinel AMI Validation project was to:

- develop and design an abstraction and adjudication process to use when full text medical record review is required to confirm a coded diagnosis; and
- test this approach by validating a code algorithm for acute myocardial infarction (AMI).

## Participants

The Mini-Sentinel AMI Validation project was a collaboration between the FDA, the Mini-Sentinel Operations Center, and selected Academic and Data Partners. Four Mini-Sentinel Data Partners participated in this project: (1) HealthCore, Inc.; (2) Humana; (3) three member health plans within the Kaiser Permanente Center for Effectiveness and Safety Research; and (4) two member health plans within the HMO Research Network.

## Design

### (1) AMI Case Identification

**Goal:** Establish ICD-9-CM-based algorithm to identify patients hospitalized for AMI within the Mini-Sentinel Distributed Database

**Approach:** Reviewed previous validation studies. Considered using a broad algorithm (incorporating Acute Coronary Syndrome codes, or codes to capture death after ER discharge).

**Algorithm:** Include ICD-9 hospital discharge codes (a principal or primary discharge code only) of 410.x0 and 410.x1.

### (2) AMI Case Retrieval

**Goal:** Establish and carry out procedure for chart retrieval and extraction, ensuring patient privacy, collecting and transferring the minimal amount of de-identified information needed to validate potential cases of AMI.

**Approach:**

- Identify required chart components (examples: EKG's, cardiac biomarkers, dictated doctor notes).
- Determine whether chart abstraction would take place centrally or in a locally distributed fashion; (Centralized approach was chosen)
- Establish protocols for ensuring the privacy and security of data and for explaining the status of this effort as a public health surveillance activity not under the oversight of IRBs.

### (3) Abstraction

**Goal:** Design abstraction form and train 2 nurse abstractors to gather key data for AMI validation.

**Approach:** 36-item abstraction form included demographic information, brief medical history, biomarker data, EKG copies, cardiac test results and disposition at discharge.

### (4) Adjudication

**Goal:** Design protocol-driven Adjudication process

**Approach:** Protocol developed based on American Heart Association Universal Definition of MI. Two UMass Cardiologists independently reviewed each case and classified as (1) Definite MI; (2) Probable MI; (3) No MI; or (4) Unable to Determine. Cardiologists met to reach consensus in cases where they differed.

### (5) Calculation of PPV (Positive Predictive Value)


**Goal:** Calculate PPV of algorithm (ratio of confirmed AMI cases to all identified cases)

**Approach:**


$$PPV = \frac{\text{Definite} + \text{Probable AMI}}{\text{All retrieved cases}}$$

## RESULTS


### Percent of Requested Charts that were Obtained (93% overall)




### Availability of Critical Chart Components



### Average Size of Chart (Pages)



### Availability of Cardiac-Specific Chart Components



Note: DP1 through 4 indicates Data Partners 1-4.

### Positive Predictive Value of AMI Identification Algorithm

DATA PARTNER	YES MI	NO MI	TOTAL # OF CHARTS	PPV (%)	95 % CONFIDENCE INTERVAL
DP1	26	6	32	81.3	64.7, 91.1
DP2	29	9	38	76.3	60.8, 87.0
DP3	33	2	35	94.3	81.4, 98.4
DP4	35	3	38	92.1	79.2, 97.3
OVERALL	123	20	143	86.0	79.4, 90.8

#### Subgroup PPV's:

age <75 (74 charts) = 94.6% (95% CI 86.9 to 97.9)  
age 75+ (53 charts) = 79.2% (66.5 to 88.0)  
males (76 charts) = 93.4% (88.5 to 97.2)  
females (67 charts) 77.6% (63.3 to 85.9)  
Lower PPV for females: driven by the women in 75+ age group  
Women <75 (29 charts) 93.1% (78.0 to 98.1);  
Women 75+ (27 charts) 70.4% (51.5 to 84.1)

## Conclusions

A PPV of 86% may be considered adequate for some surveillance activities relevant to medication and device safety, but not for others.

Further research may be merited examining between-age group and between-gender differences in the positive predictive value of this AMI identification algorithm.